iRhythm Technologies (NASDAQ:IRTC) Issues Quarterly Earnings Results

Key Points

• iRhythm exceeded quarterly expectations: Revenue rose 20.1% to $224.2 million, topping estimates, while EPS reached $0.58 versus the $0.04 loss analysts expected. Adjusted EBITDA margin was 19.3% and free cash flow reached a record $37.5 million.
• The company raised its 2026 outlook to $880 million-$890 million in revenue and a 13%-14% adjusted EBITDA margin, supported by continued volume growth and cost efficiencies.
• Growth initiatives include the pending VitalConnect acquisition and a next-generation algorithm expected to reduce technician review time and deliver about $100 million in cumulative savings over five years. Key risks include regulatory matters, acquisition approval and integration, a $50 million Baxter litigation settlement, and cybersecurity concerns.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) issued its earnings results on Thursday. The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.62, FiscalAI reports. iRhythm Technologies had a negative return on equity of 10.26% and a negative net margin of 3.53%.The business had revenue of $224.17 million during the quarter, compared to the consensus estimate of $219.30 million.

Here are the key takeaways from iRhythm Technologies' conference call:

• Q2 revenue rose 20.1% to $224.2 million, marking the seventh consecutive quarter of more than 20% growth. Adjusted EBITDA margin reached 19.3%, free cash flow was a record $37.5 million, and adjusted net income improved to $19.3 million.
• iRhythm raised its 2026 outlook to $880 million-$890 million in revenue and a 13%-14% adjusted EBITDA margin, citing sustained volume growth, operating efficiencies, and disciplined expense management.
• The pending VitalConnect acquisition is intended to broaden iRhythm’s MCT offering and add capabilities in inpatient monitoring, hospital-to-home care, remote patient monitoring, and multi-vital sensing. Management expects revenue contribution beginning in 2027 and believes the combined company can reach its previously stated 15% adjusted EBITDA margin target in 2027.
• FDA clearance of iRhythm’s third-generation algorithm could reduce technician review time by up to 50% and generate approximately $100 million in cumulative cost savings over five years after its planned first-half 2027 launch.
• Key execution and regulatory risks remain, including the pending FDA warning-letter resolution, HSR review and integration of VitalConnect, and continued uncertainty around the timing of Zio MCT clearance. The company also agreed to pay $50 million to settle litigation with Baxter, while a June cybersecurity incident involved data exfiltration despite no reported material operational or financial impact.

iRhythm Technologies Trading Up 2.9%

Shares of NASDAQ:IRTC traded up $3.62 during midday trading on Thursday, reaching $128.12. 1,205,295 shares of the company's stock were exchanged, compared to its average volume of 607,483. The stock has a market cap of $4.21 billion, a price-to-earnings ratio of -148.98 and a beta of 1.30. iRhythm Technologies has a fifty-two week low of $100.85 and a fifty-two week high of $212.00. The firm's 50 day simple moving average is $114.51 and its two-hundred day simple moving average is $124.83. The company has a debt-to-equity ratio of 4.03, a current ratio of 5.17 and a quick ratio of 4.98.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on IRTC shares. Bank of America dropped their price objective on shares of iRhythm Technologies from $225.00 to $180.00 and set a "buy" rating for the company in a report on Monday, May 18th. HC Wainwright reiterated a "buy" rating on shares of iRhythm Technologies in a report on Monday, June 1st. JPMorgan Chase & Co. dropped their price target on shares of iRhythm Technologies from $215.00 to $175.00 and set an "overweight" rating for the company in a research note on Friday, May 1st. Weiss Ratings upgraded shares of iRhythm Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, June 18th. Finally, Wells Fargo & Company reduced their price target on shares of iRhythm Technologies from $200.00 to $180.00 and set an "overweight" rating on the stock in a research report on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $184.71.

Insider Buying and Selling

In related news, Director Abhijit Y. Talwalkar bought 5,312 shares of the stock in a transaction on Monday, May 11th. The stock was bought at an average price of $10.71 per share, with a total value of $56,891.52. Following the completion of the purchase, the director directly owned 25,611 shares in the company, valued at $274,293.81. This represents a 26.17% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.98% of the stock is owned by insiders.

Hedge Funds Weigh In On iRhythm Technologies

Large investors have recently made changes to their positions in the stock. Measured Wealth Private Client Group LLC acquired a new stake in iRhythm Technologies in the 3rd quarter valued at approximately $30,000. Employees Retirement System of Texas purchased a new position in shares of iRhythm Technologies during the third quarter worth $36,000. Smartleaf Asset Management LLC grew its stake in shares of iRhythm Technologies by 63.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 323 shares of the company's stock valued at $58,000 after buying an additional 125 shares in the last quarter. Harvest Fund Management Co. Ltd acquired a new stake in shares of iRhythm Technologies in the third quarter valued at $69,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of iRhythm Technologies in the 4th quarter valued at $71,000.

About iRhythm Technologies

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company's flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm's digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source